Berkeley, California (EastBayDaily) — The company also plans to have a corporate overview presentation at the Oppenheimer 19th Annual Healthcare Conference in New York City on November 3, 2008 at 11:20 a.m. EST (8:20 a.m. PST). Michael S. Ostrach, Vice President and Chief Business Officer of Dynavax, will present at this conference. To access the live audio webcast and the subsequent archived audio recording of the presentation, please log onto Dynavax’s website at http://investors.dynavax.com/events.cfm.
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of infectious diseases, respiratory diseases and cancer. The company’s novel Toll-like Receptor 9 (TLR9) agonist products are based on its proprietary immunostimulatory sequences (ISS), which are short DNA sequences that stimulate the innate immune response. Dynavax’s clinical product candidates include: HEPLISAVTM, a hepatitis B vaccine partnered with Merck & Co., Inc.; a therapy for hepatitis B; and therapies for cancer and hepatitis C funded by Symphony Dynamo, Inc. The company’s preclinical pipeline includes an asthma and COPD drug candidate partnered with AstraZeneca and a Universal Flu vaccine. For more information visit http://www.dynavax.com.